RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
DOD Biotech PCL - Stock

DOD Biotech PCL Stocks 2024

DOD Biotech PCL Stocks

450.41 M

Ticker

DOD.BK

ISIN

TH8569010003

In 2024, DOD Biotech PCL had 450.41 M outstanding stocks, a 9.59% change from the 410.98 M stocks in the previous year.

The DOD Biotech PCL Stocks history

YEARNUMBER OF STOCKS (undefined THB)
2023450.41
2022410.98
2021410.98
2020410.98
2019410
2018360.27
2017300
2016192.82
2015101.75
2014360.71

DOD Biotech PCL shares outstanding

The number of shares was DOD Biotech PCL in 2023 — This indicates how many shares 450.414 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue DOD Biotech PCL earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates DOD Biotech PCL's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of DOD Biotech PCL’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating DOD Biotech PCL's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

DOD Biotech PCL Aktienanalyse

What does DOD Biotech PCL do?

DOD Biotech PCL is a Thai biotechnology company specializing in the production of pharmaceuticals, diagnostics, and research products. Established in 2004, the company has become one of the most reputable biotechnology companies in Thailand. Its business model is based on the development and manufacturing of products used in medicine, veterinary medicine, and research. DOD Biotech PLC focuses on continually evolving and adapting its products to meet customer needs. Its main areas of focus are the production of pharmaceuticals, particularly anti-cancer drugs, diabetes medications, cardiovascular medications, and infection treatments. Additionally, the company manufactures diagnostics for disease early detection and precise diagnosis. It also offers a variety of products for research purposes. DOD Biotech PCL has partnerships with several companies in other countries, particularly in Asia and Europe. Its largest partner is the Indian company Sun Pharma, with which it has had a successful collaboration for many years. The company is known for its high-quality standards and is certified to ISO 9001:2015 and follows the Good Manufacturing Practices (GMP) required by the Thai FDA. DOD Biotech PCL has received international recognition, including the Frost & Sullivan Thailand Excellence Award and being recognized as a top 30 company in Thailand in 2020. Over the years, the company has built a loyal customer base that appreciates its high-quality products and excellent customer service. It has a strong online presence to better reach and serve its customers. In summary, DOD Biotech PCL is a leading biotechnology company in Thailand with a wide range of pharmaceuticals, diagnostics, and research products. It has earned an excellent reputation for its high-quality standards and top-notch customer service. With its strong online presence and partnerships with other companies in Asia and Europe, DOD Biotech PCL will undoubtedly remain an important player in the global healthcare market in the future. DOD Biotech PCL ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating DOD Biotech PCL's Shares Outstanding

DOD Biotech PCL's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in DOD Biotech PCL’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding DOD Biotech PCL’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in DOD Biotech PCL’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about DOD Biotech PCL Stock

How many stocks are there of DOD Biotech PCL?

The current number of stocks of DOD Biotech PCL is 450.41 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of DOD Biotech PCL are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of DOD Biotech PCL evolved in recent years?

The number of shares of DOD Biotech PCL has increased by 9.59% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. DOD Biotech PCL as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of DOD Biotech PCL?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does DOD Biotech PCL pay?

Over the past 12 months, DOD Biotech PCL paid a dividend of 0.05 THB . This corresponds to a dividend yield of about 2.27 %. For the coming 12 months, DOD Biotech PCL is expected to pay a dividend of 0 THB.

What is the dividend yield of DOD Biotech PCL?

The current dividend yield of DOD Biotech PCL is 2.27 %.

When does DOD Biotech PCL pay dividends?

DOD Biotech PCL pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of DOD Biotech PCL?

DOD Biotech PCL paid dividends every year for the past 0 years.

What is the dividend of DOD Biotech PCL?

For the upcoming 12 months, dividends amounting to 0 THB are expected. This corresponds to a dividend yield of 0 %.

In which sector is DOD Biotech PCL located?

DOD Biotech PCL is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von DOD Biotech PCL kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of DOD Biotech PCL from 5/20/2020 amounting to 0.05 THB, you needed to have the stock in your portfolio before the ex-date on 3/13/2020.

When did DOD Biotech PCL pay the last dividend?

The last dividend was paid out on 5/20/2020.

What was the dividend of DOD Biotech PCL in the year 2023?

In the year 2023, DOD Biotech PCL distributed 0 THB as dividends.

In which currency does DOD Biotech PCL pay out the dividend?

The dividends of DOD Biotech PCL are distributed in THB.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von DOD Biotech PCL

Our stock analysis for DOD Biotech PCL Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DOD Biotech PCL Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.